AI in Pharmacovigilance: Systems, Agents & Governance · Section 13.10
~7 min read · The Drug Safety Coach — Global PV Career Course
Key points
Full text
Every earlier module in this course that touched AI treated "human in the loop" as a single principle: a human reviews, a human signs off. This lesson makes that principle more precise, because HITL is genuinely not one thing — it’s a spectrum of five distinct relationships between a human decision-maker and an automated system, and knowing which point on that spectrum a given workflow actually occupies is a real, practical distinction, not academic hair-splitting.
At one end sits full automation — AI makes the final decision, no human review before action — and the regulatory verdict here is unambiguous: not compliant with any current framework for safety-critical PV decisions, full stop. One step up is human-on-the-loop, where AI acts first and a human reviews after the fact; this is acceptable only for genuinely low-stakes activities like internal workflow routing, and explicitly not acceptable for case processing or signal actions, because errors here may only be discovered after submission or after a label action has already happened.
Human-in-the-loop — AI proposes, a human validates before any action is taken — is the actual regulatory gold standard for every safety-critical PV activity this course has covered, and the definition matters precisely: the human reviewer has to have genuine authority to accept, reject, or modify the AI’s output, not just rubber-stamp it. This is the level every regulatory framework in Lesson 13.8 converges on as the pre-action validation requirement.
Human-over-the-loop is a distinct level worth understanding on its own terms: a human defines the rules and thresholds, and AI then operates autonomously within those defined boundaries, with the human providing strategic rather than case-by-case oversight. This is appropriate specifically for population-level surveillance, where reviewing every individual case would be impractical — a legitimate, lower-risk use of automation precisely because the stakes and the governance model both scale differently than individual case decisions. And at the far end, augmented cognition — AI providing context, precedent, and pattern recognition to support a decision the human would have made anyway, just faster and with more information available — is explicitly named as the gold standard specifically for complex decisions, because an AI failure here results in a less-informed human decision, not an automated error reaching a patient or a regulator unreviewed.
Important
The commercial pressure runs one direction: as AI systems get faster and more accurate, there’s constant pressure to slide from human-in-the-loop toward human-on-the-loop, or even full automation, for certain tasks. Resisting that pressure for safety-critical decisions isn’t about regulatory box-ticking — the failure modes of unreviewed AI errors in pharmacovigilance are patient harm, regulatory sanctions, and eroded public trust in drug safety systems. That’s the actual stake, not just a compliance technicality.
Quick check
Test yourself before moving on — no pressure, just click an answer.
1. What is the regulatory verdict on "full automation" (no HITL) for safety-critical PV decisions?
2. What distinguishes human-in-the-loop (the regulatory gold standard) from human-on-the-loop (limited use only)?
The HITL Spectrum — click a level